Extended Data Fig. 1: Trypanosoma vivax vaccine candidate antigens, organization of the protection screen and antibody titres.

a, Vaccine candidates were expressed as soluble recombinant proteins in HEK293 cells, purified and resolved by SDS–PAGE to determine protein integrity and purity. For uncropped gel images, see Supplementary Fig. 1. b, Mice were vaccinated with a protein-in-alum formulation using a prime and two-boost regime and rested before challenge with the luciferase-expressing T. vivax parasite line and parasitaemia quantified using bioluminescent imaging. Vaccine candidates were tested in cohorts containing two control cages that were infected first and last to ensure any effect on the reduction of parasite multiplication was not confounded by the loss of parasite virulence. c, Parasite multiplication was identical in mice treated with adjuvant alone compared to naive mice. A group of five mice were immunized three times with alum alone (filled circles) and rested for six weeks and the infection with bioluminescent T. vivax was compared to naive mice (open circles). Data points represent individual mice; grey shading indicates background bioluminescence. d, Serum dilutions for the half-maximal responses for each antigen. Data points are individual mice and bars represent mean ± s.d.; n = 5. ND, not determined. Grey stars indicate no detectable response.

Source data